Second-Quarter Consumer Health Results Bring J&J Relief From Year-Ago Sales Plummet
Segment's Results Likely Better Than Remainder Of 2021, J&J And Analyst Say
In first of what could be similar April-June earnings results from major consumer health firms, J&J reports 9.2% operational growth to $3.74bn in sales. Worldwide consumer health chief Thibaut Mongon touts segment’s results and outlook but says similar growth in second half isn’t assured.
You may also be interested in...
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
J&J Consumer Health's worldwide chairman Thibaut Mongon told the recent Barclays Consumer Staples conference that COVID-19 had accelerated the shift to digital and what consumers expect from OTC brands.
J&J's CEO Alex Gorsky is stepping down after almost 10 years in the role and will be replaced by vice chairman of the executive committee Joaquin Duato.